Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells - PubMed (original) (raw)
Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells
Atsushi Nakagawa et al. Auton Neurosci. 2004.
Abstract
We previously reported that afferent signals of the rat hepatic vagus increased upon intraportal appearance of insulinotropic hormone glucagon-like peptide-1(7-36) amide (GLP-1), but not glucose-dependent insulinotropic polypeptide (GIP). To obtain molecular evidence for the vagal chemoreception of GLP-1, the concept derived from those electrophysiological observations, receptor gene expressions of GLP-1 and GIP in the rat nodose ganglion were examined by means of reverse transcriptase-mediated polymerase chain reaction (RT-PCR) and Northern blot analysis. Gene expression of the GLP-1 receptor was clearly detected by both RT-PCR and Northern blot analysis. In situ hybridization study confirmed that the expression occurs in neuronal cells of the ganglion. As to the GIP receptor, RT-PCR amplified the gene transcript faintly though Northern blot analysis failed to detect any messages. However, semi-quantitative RT-PCR revealed that the ratio of the gene expression level of the GIP receptor to that of the GLP-1 receptor was less than 1:250, indicating that receptor gene expression of GIP is practically negligible in the ganglion. Additionally, an equal level of GLP-1 receptor gene expressions between left- and right-side ganglia was evidenced by semi-quantitative RT-PCR, implying possible extrahepatic occurrence of vagal GLP-1 reception in addition to the reception through the hepatic vagus (originating from the left-side ganglion). The present results offer, for the first time, the molecular basis for the vagal chemoreception of GLP-1 via its specific receptor.
Similar articles
- Evaluation of the insulinotropic and glucose-lowering actions of zebrafish GIP in mammalian systems: Evidence for involvement of the GLP-1 receptor.
Graham GV, Conlon JM, Abdel-Wahab YH, Gault VA, Flatt PR. Graham GV, et al. Peptides. 2018 Feb;100:182-189. doi: 10.1016/j.peptides.2017.11.007. Epub 2017 Nov 20. Peptides. 2018. PMID: 29157578 - Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat.
Bucinskaite V, Tolessa T, Pedersen J, Rydqvist B, Zerihun L, Holst JJ, Hellström PM. Bucinskaite V, et al. Neurogastroenterol Motil. 2009 Sep;21(9):978-e78. doi: 10.1111/j.1365-2982.2009.01317.x. Epub 2009 May 13. Neurogastroenterol Motil. 2009. PMID: 19453518 - Glucagon receptors on human islet cells contribute to glucose competence of insulin release.
Huypens P, Ling Z, Pipeleers D, Schuit F. Huypens P, et al. Diabetologia. 2000 Aug;43(8):1012-9. doi: 10.1007/s001250051484. Diabetologia. 2000. PMID: 10990079 - GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
Hansotia T, Drucker DJ. Hansotia T, et al. Regul Pept. 2005 Jun 15;128(2):125-34. doi: 10.1016/j.regpep.2004.07.019. Regul Pept. 2005. PMID: 15780432 Review. - Glucagon-like peptide-1 and control of insulin secretion.
Thorens B. Thorens B. Diabete Metab. 1995 Dec;21(5):311-8. Diabete Metab. 1995. PMID: 8586147 Review.
Cited by
- Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty.
Plamboeck A, Veedfald S, Deacon CF, Hartmann B, Wettergren A, Svendsen LB, Meisner S, Hovendal C, Knop FK, Vilsbøll T, Holst JJ. Plamboeck A, et al. Eur J Endocrinol. 2013 Jul 6;169(2):187-201. doi: 10.1530/EJE-13-0264. Print 2013 Aug. Eur J Endocrinol. 2013. PMID: 23704713 Free PMC article. Clinical Trial. - Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.
Holst JJ, Deacon CF. Holst JJ, et al. Diabetologia. 2005 Apr;48(4):612-5. doi: 10.1007/s00125-005-1705-7. Epub 2005 Mar 10. Diabetologia. 2005. PMID: 15759106 No abstract available. - The gut microbiota to the brain axis in the metabolic control.
Grasset E, Burcelin R. Grasset E, et al. Rev Endocr Metab Disord. 2019 Dec;20(4):427-438. doi: 10.1007/s11154-019-09511-1. Rev Endocr Metab Disord. 2019. PMID: 31656993 Free PMC article. Review. - Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats.
Liu WJ, Jin HY, Lee KA, Xie SH, Baek HS, Park TS. Liu WJ, et al. Br J Pharmacol. 2011 Nov;164(5):1410-20. doi: 10.1111/j.1476-5381.2011.01272.x. Br J Pharmacol. 2011. PMID: 21323903 Free PMC article. - Ability of GLP-1 to decrease food intake is dependent on nutritional status.
Ronveaux CC, de Lartigue G, Raybould HE. Ronveaux CC, et al. Physiol Behav. 2014 Aug;135:222-9. doi: 10.1016/j.physbeh.2014.06.015. Epub 2014 Jun 21. Physiol Behav. 2014. PMID: 24955496 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials